Collaboration holds the promise to reduce overtreatment with integrated AI-powered pathology workflows

OSLO and PHILADELPHIA, Aug. 30, 2023 /PRNewswire-PRWeb/ — DoMore Diagnostics, a leader in deep learning precision diagnostics for digital pathology, and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help pathologists predict outcomes for colorectal cancer (CRC) patients. The collaboration paves the way for integrating artificial intelligence (AI)-powered clinical decision support into routine pathology workflows, unlocking new insights that can guide increasingly precise treatment decisions and ensure patients receive optimal care.

CRC is the third most common and second most deadly cancer worldwide[1]. While adjuvant chemotherapy may be provided after primary surgery to prevent the disease from recurring, predicting when it will lead to overtreatment can be challenging. Up to 90% of patients with stage II and stage III cases do not realize any benefit from adjuvant chemotherapy and only suffer side effects.[2]

The partnership paves the way for delivering an integrated solution that combines DoMore Diagnostics’ CE-IVDD marked Histotype Px® Colorectal* digital biomarker with Proscia’s CE-IVDR marked Concentriq® Dx** enterprise pathology platform. Data previously published in The Lancet[3] and Lancet Oncology[4] demonstrated that Histotype Px Colorectal can successfully predict outcomes for stage II and stage III CRC patients. Combined with tumor and lymph node status, the test report provides information about patients’ risk profile and 5-year cancer-specific survival to inform the decision to use adjuvant chemotherapy.

“We have proven that Histotype Px Colorectal can offer valuable insight to guide personalized treatment decisions and help improve patient outcomes,” said Torbjørn Furuseth, MD, CEO and Co-founder of DoMore Diagnostics. “We must now continue to integrate the algorithm into pathologists’ routine operations for it to make the greatest impact. As leading laboratories are increasingly turning to Proscia, our partnership paves the way for accelerating the adoption of its solution.”

Concentriq Dx is an enterprise pathology platform that drives primary diagnostic workflows for reference laboratories, hospitals, and health systems of all sizes. It offers a compelling user experience that allows pathologists to quickly transition away from the microscope and work with speed and ease. An open platform, Concentriq Dx is designed to integrate AI applications from Proscia, Proscia’s customers, and leading third parties, including DoMore Diagnostics, into routine workflows so that laboratories can realize the full promise of pathology’s computational future at scale.

“Laboratories are increasingly demanding an open approach to digital pathology,” said Stephan Fromme, Proscia’s Head of Strategic Alliances. “They recognize that unlocking more utility for pathologists and patients means tapping into the collective power of a growing number of solutions. We look forward to adding Histotype Px Colorectal to our ecosystem to help our users make increasingly personalized diagnoses that can ultimately reduce overtreatment for more patients.”

To learn more about Concentriq Dx and see a demo of Histotype Px Colorectal, visit Proscia at booth 7 on the third-floor foyer during the 35th European Congress of Pathology.

*Histotype Px is CE-marked under IVDD. For Research Use only outside the EU.

**Concentriq Dx is CE-marked under IVDR.

About DoMore Diagnostics

DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.

For more information, please visit: 

www.domorediagnostics.com

.

LinkedIn

.

Lancet Oncology

.

About Proscia

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit 

proscia.com

.

[1] Worldwide Cancer Data. World Cancer Research Fund International. (2022, April 14). 

https://www.wcrf.org/cancer-trends/worldwide-cancer-data/

[2] Approx. 96-98% in stage II and 80% in stage III. Taieb et al. Cancer Treat Rev (2019). 

https://doi.org/10.1016/j.ctrv.2019.02.002

[3] Skrede et al. Lancet (2020): 

https://doi.org/10.1016/S0140-6736(19)32998-8

[4] Kleppe et al. Lancet Oncology (2022): 

https://doi.org/10.1016/S1470-2045(22)00391-6

Media Contact

Sydney Fenkell, Proscia, 1 215-816-3436, sydney@proscia.com, www.proscia.com

View original content to download multimedia:https://www.prweb.com/releases/domore-diagnostics-and-proscia-partner-to-inform-personalized-treatment-decisions-for-colorectal-cancer-patients-301913736.html

SOURCE Proscia